Jeremy Welsch University of Michigan, Medical School
3 protocols

Longping Tse University of North Carolina at Chapel Hill
28 protocols

Masfique Mehedi University of North Dakota
3 protocols

Ran Chen Zhejiang JFK Biological Technology Co. Ltd.
6 protocols

Reviewer
George William Carnell
  • Post-Doc, University of Cambridge
Research focus
  • 2 Author merit

Education

PhD, University of Kent, 2018

Lab information

Heeney lab

2 Protocols published
A Lentiviral Pseudotype ELLA for the Measurement of Antibodies Against Influenza Neuraminidase
Authors:  Fabrizio Biuso, George Carnell, Emanuele Montomoli and Nigel Temperton, date: 07/20/2018, view: 5763, Q&A: 0
This protocol describes the rapid and safe production of lentiviral pseudotypes characterized by a lentiviral core containing a reporter, in conjunction with avian influenza haemagglutinin (HA) and human neuraminidase (NA) glycoproteins on the ...
An Optimized Method for the Production Using PEI, Titration and Neutralization of SARS-CoV Spike Luciferase Pseudotypes
Authors:  George Carnell, Keith Grehan, Francesca Ferrara, Eleonora Molesti and Nigel Temperton, date: 08/20/2017, view: 13628, Q&A: 1
The protocol outlined represents a cost-effective, rapid and reliable method for the generation of high-titre viral pseudotype particles with the wild-type SARS-CoV spike protein on a lentiviral vector core using the widely available transfection ...
5 Protocols reviewed
Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike

The use of recombinant lentivirus pseudotyped with the coronavirus Spike protein of SARS-CoV-2 would circumvent the requirement of biosafety-level 3 (BSL-3) containment facilities for the handling of SARS-CoV-2 viruses. Herein, we describe a fast

...
More >
Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike

The use of recombinant lentivirus pseudotyped with the coronavirus Spike protein of SARS-CoV-2 would circumvent the requirement of biosafety-level 3 (BSL-3) containment facilities for the handling of SARS-CoV-2 viruses. Herein, we describe a fast

...
More >
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.